Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways

Blood

Volumn 95, Issue 7, 2000, Pages 2391-2396

  Witt, Olaf ^a   Sand, Katrin ^a   Pekrun, Arnulf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BUTYRIC ACID; HEMOGLOBIN; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ERYTHROID CELL; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034176006     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2391.007k21_2391_2396     Document Type: Article

References (57)

1. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem. 1982;42:65.
2. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemic cells. Cancer. 1983;51:9.
3. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol. 1987;23:1283.
4. Brettmann LR, Chaturvedi PR. Pharmacokinetics and safety of single oral doses of VX-366 (isobutyramide) in healthy volunteers. J Clin Pharmacol. 1996;36:617.
5. Piscitelli SC, Thibault A, Figg WD, et al. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol. 1995;35:368.
6. Boudoulas SB, Lush RM, McCall NA, Samid D, Reed E, Figg WD. Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. Ther Drug Monit. 1996;18: 714.
7. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. TIBS. 1995;20: 117.
8. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49.
9. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726.
10. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukaemia cell line K562. Nature. 1979;278:364.
11. Payne DM, Rossomando AJ, Martino P, et al. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 1991;10:885.
12. Derijard B, Hibi M, Wu IH, et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025.
13. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265:808.
14. Favata M, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen activated protein kinase kinase. J Biol Chem. 1998;273: 18,623.
15. DeSilva DR, Jones EA, Favata M, et al. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol. 1998;160:4175.
16. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686.
17. Cuenda A, Rouse J, Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364:229.
18. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739.
19. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279:1453.
20. Gum JR, Kam WK, Byrd JC, Hicks JW, Sleisinger MH, Kim YS. Effects of sodium butyrate on human colonic adenocarcinoma cells. J Biol Chem. 1987;262:1092.
21. Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res. 1984;44:3961.
22. Rocchi P, Ferreri AM, Magrini E, Perocco P. Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines. Anticancer Res. 1998;18:1099.
23. Nakagawa T, Nakao Y, Matsui T, et al. Effects of sodium n-butyrate on alpha-fetoprotein and albumin secretion in the human hepatoma cell line PLC/PRF/5. Br J Cancer. 1985;51:357.
24. Chen ZX, Breitmann TR. Tributyrin: a prodrug of butyric acid for potential clinical applications in differentiation therapy. Cancer Res. 1994;54: 3494.
25. Boyd AW, Metcalf D. Induction of differentiation in HL-60 leukemia cells: a cell cycle dependent all-or-none event. Leuk Res. 1984;8:27.
26. Breitmann TR, He R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL-60. Cancer Res. 1990;50: 6268.
27. Gillet R, Jeannesson P, Sefraoui H, et al. Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells. Cancer Chemother Pharmacol. 1998;41:252.
28. Halgunset J, Lamvik T, Espevik T. Butyrate effects on growth, morphology, and fibronectin production in PC-3 prostatic carcinoma cells. Prostate. 1988;12:65.
29. Kyritsis A, Joseph G, Chader GJ. Effects of butyrate, retinol, and retinoic acid on human Y-79 retinoblastoma cells growing in monolayer cultures. J Natl Cancer Inst. 1984;73:649.
30. Langdon SP, Hawkes MM, Hay FG, et al. Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cells. Cancer Res. 1988;48:6161.
31. Graham KA, Buick RN. Sodium butyrate induces differentiation in breast cancer cell lines expressing the estrogen receptor. J Cell Physiol. 1988; 136:63.
32. Yamashita T, Wakao H, Miyajima A, Asano S. Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line. Cancer Res. 1998;58:556.
33. Cuisset L, Tichonicky L, Jaffrey P, Delpech M. The effects of butyrate on transcription are mediated through activation of a protein phosphatase. J Biol Chem. 1997;272:24,148.
34. Shelly C, Petruzzelli L, Herrera R. PMA-induced phenotypic changes in K562 cells: MAPK-dependent and -independent events. Leukemia. 1998; 12:1951.
35. Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol. 1997; 17:1947.
36. Mansour SJ. Marten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994; 265:966.
37. Brunet A, Pages G, Pouysseger J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene. 1994; 9:3379.
38. Kortenjann M, Thomae O, Shaw PE. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase ERK2. Mol Cell Biol. 1994;14:4815.
39. Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J, Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90:8319.
40. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179.
41. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841.
42. Minshull J, Sun H, Tonks NK, Murray AW. A MAP-kinase dependent spindle assembly checkpoint in Xenopus egg extracts. Cell. 1994;79:475.
43. Ray LB, Sturgill TW. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 and adipocytes that phosphorylate microtubule-associated protein 2 in vitro. Proc Natl Acad Sci U S A. 1987; 84:1502.
44. Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64:235.
45. Rausch O, Marshall CJ. Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates Ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway. Mol Cell Biol. 1997;17:1170.
46. Nagata Y, Nishida E, Todokoro K. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3. Blood. 1997;89: 2664.
47. Nagata Y, Moriguchi T, Nishida E, Todokoro K. Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. Blood. 1997;90:929.
48. Foltz IN, Schrader JW. Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4. Blood. 1997;89:3092.
49. Foltz IN, Lee JC, Young PR, Schrader JW. Memopoietic growth factors with the exception of interleukin-4 activate the p38 mitogen-activated protein kinase pathway. J Biol Chem. 1997;272: 3296.
50. Nagata Y, Takahashi N, Davis RJ, Todokoro K. Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation. Blood. 1998;92:1859.
51. Wakselman M, Cerutti I, Chany C. Anti-tumor protection induced in mice by fatty acid conjugates: alkyl butyrates and poly(ethylene glycol) dibutyrates. Int J Cancer. 1990;46:462.
52. Planchon P, Raux H, Magnien V, et al. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells. Int J Cancer. 1991;48:443.
53. Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelmann A. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer. 1991;49:66.
54. Nudelmann A, Ruse M, Aviram A, et al. Novel anticancer prodrugs of butyric acid. J Med Chem. 1992;35:687.
55. Samid D, Ram Z, Hudgins WR, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 1994;54:891.
56. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81.
57. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93: 1790.